1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
MDA-MB-436 is a triple-negative breast cancer (TNBC) cell line derived from the pleural effusion of a patient with breast adenocarcinoma. The splice donor site of exon 20 in MDA-MB-436 cell line harbored the 5396 + 1G>A mutation, which is accompanied by the loss of the remaining BRCA1 allele. MDA-MB-436 is characterized as a claudin-low TNBC cell line that exhibits a mesenchymal-cell-like morphology. MDA-MB-436 exhibits pleomorphism, and a significant proportion of the cells show strong reactivity when subjected to indirect immunofluorescence staining using an anti-tubulin antibody. MDA-MB-436 can be cultured in Leibovitz’s L-15 medium with 10% FBS.
Why choose MDA-MB-436 from AcceGen?
MDA-MB-436 from AcceGen has high standards of sterility, negative for contamination from bacterial, fungal, and mycoplasma sources (confirmed through PCR analysis). The post-thaw viability of MDA-MB-436 exceeds 95%, indicating excellent preservation and functionality even after cryopreservation. This high viability rate is crucial for reliable and robust experimental results. The growth characteristics of MDA-MB-436 are evaluated based on their morphology and immunocytochemistry of multiple undifferentiation markers. Overall, AcceGen performed comprehensive assessments to ensure its reliability for scientific uses.
| Product Code | MDA_MB_436; MDA MB 436; MDA-Mb-436; MDA-MB436; MDAMB436; MDA-436; MDA436; MB436; MD Anderson-Metastatic Breast-436 |
| Species | Human |
| Cat.No | ABC-TC0655 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
MDA-MB-436 can be used as a model to identify the effect of novel drugs or existing agents on breast cancer patients, and identify growth factors in the tumor growth and potential targets for a novel therapeutic strategy for TNBCs. It’s interesting that retinoic acid(RA), an existing anti-cancer agent, decreases the tumor growth of basal-like TNBC cell line (such as MDA-MB-468) but increases the tumor growth of claudin-low TNBC (such as MDA-MB-231, MDA-MB-436). The following investigation may be the determination of key factors in the pathway of RA to further understand the difference between basal-like and claudin-low TNBC, and also benefit to diagnose the type of breast cancer and speculate the response of patient tumors to a novel therapeutic strategy.
